Sponsor Pipeline

Cullinan Therapeutics Inc. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
10
Active Trials
4
Recruiting
9
Disease Areas
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-08-12 NCT07041099
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in…
Trial sites expanded: 11 -> 14 locations
New Trial Filings, Last 30 Days
First PostedTrialPhaseStatus
2026-07-31 NCT07738822 A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA Phase 1/2 Not Yet Recruiting
2026-07-23 NCT07722767 A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients Phase 1 Not Yet Recruiting
Active Trials by Phase
Phase 1/2
2
Phase 1
8
Active Trials
NCT IDTitleConditionStatus
Phase 1/2
NCT04036682 A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer Non Small Cell Lung Cancer Active, Not Recruiting
NCT07738822 A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA Immune Thrombocytopenia (ITP) Not Yet Recruiting
Phase 1
NCT05143996 CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or… Relapsed/Refractory Acute Myeloid Leukemia (AML) Recruiting
NCT06994143 A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in… Rheumatoid Arthritis (RA Recruiting
NCT06613360 A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in… SLE Recruiting
NCT07041099 A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in… Sjögren Recruiting
NCT05879744 A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin… NHL Active, Not Recruiting
NCT06381141 A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory… Multiple Myeloma Active, Not Recruiting
NCT05117476 A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors Advanced Solid Tumor Active, Not Recruiting
NCT07722767 A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients AML (Acute Myeloid Leukemia) Not Yet Recruiting
Disease Areas
Get alerts when Cullinan Therapeutics Inc.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free